Preparation and Distribution of Adult Stem Cells

描述(由申请人提供)：这是一个竞争性的续签申请，该中心将从人类志愿者和啮齿动物的骨髓中制备成体干细胞/祖细胞，定义细胞的质量，然后将其分发给多名研究人员。我们制备的成体干细胞/祖细胞最初被称为成纤维细胞集落形成单位，然后在血液学文献中被称为骨髓基质细胞，后来被称为间充质干细胞，最近被称为多能间充质基质细胞或MSCs。自2003年6月成立以来，该中心已经向220名个人调查人员运送了451批1013瓶冷冻MSCs，其中129瓶由NIH资助(附录A)。另有41名调查人员提交了接受MSCs的MTA；其中14人由NIH资助。共有114名调查人员为这一相互竞争的续签申请提供了支持函。具体目标是：1.继续生产标准化的人骨髓间充质干细胞(HMSCs)制剂，以便分发给其他研究人员。2.继续提供具有相似特性的大鼠骨髓间充质干细胞(RMSCs)制剂，以分发给其他研究人员。3.继续提供类似的小鼠骨髓间充质干细胞(MoMSCs)制剂，以分发给其他研究人员。4.改进人骨髓间充质干细胞的分离和鉴定方法。随着我们和其他人目前努力启动MSCs的I期和II期临床试验，对完全特征化的MSCs进行实验的必要性已经变得至关重要。

DESCRIPTION (provided by applicant): This is a competing renewal application for a Center to prepare adult stem/progenitor cells from the bone marrow of human volunteers and rodents, define the quality of the cells, and then distribute them to multiple investigators. The adult stem/progenitor cells we prepare were originally referred to as fibroblastic colony forming - units, then as marrow stromal cells in the hematological literature, subsequently as mesenchymal stem cells, and most recently as multipotent mesenchymal stromal cells or MSCs. Since its establishment in June of 2003, the Center has made 451 shipments of 1,013 vials of frozen MSCs to 220 individual investigators, 129 of which are NIH funded (Appendix A). An additional 41 investigators have submitted MTAs to receive MSCs; of which 14 are NIH funded. A total of 114 investigators have provided letters of support for this competing renewal application. The Specific Aims are: 1. To continue to produce standardized preparations of human MSCs (hMSCs) for distribution to other investigators. 2. To continue to provide similarly characterized preparations of rat MSCs (rMSCs) for distribution to other investigators. 3. To continue to provide similar preparations of mouse MSCs (moMSCs) for distribution to other investigators. 4. To develop improved methods for isolating and characterizing hMSCs. The need for experiments with fully characterized MSCs has become critical with the current efforts by us and others to initiate Phase I and Phase II clinical trials with MSCs.